Telix_Main_Logo (3).png
Telix Highlights Presentations at Upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2024)
January 22, 2024 06:00 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces presentations featuring the Company’s theranostic programs at the...
Telix_Main_Logo (3).png
Telix Announces Planned Registered Public Offering and Listing in the United States
January 04, 2024 16:59 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:TLX, “Telix” or the “Company”) today announces that it is considering an initial public offering (“IPO”) of...
Telix_Main_Logo (3).png
Telix to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024 16:55 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia, Jan. 03, 2024 (GLOBE NEWSWIRE) --  Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today advises that Dr Christian Behrenbruch, Managing Director and Group CEO,...
20170406 Telix Logo.png
Telix Radiopharmaceutical Production Facility Buildout Commences
March 21, 2022 18:41 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia and BRUSSELS, Belgium, March 22, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to provide a material update on the development...
20170406 Telix Logo.png
EAU Updates Guidance for PSMA-PET Imaging
March 21, 2022 01:28 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia and LIÈGE, Belgium, March 21, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) welcomes the updated 2022 ‘Guidelines on Prostate...
20170406 Telix Logo.png
ZIRCON Phase III Kidney Cancer Imaging Study Completes Target Enrolment
March 07, 2022 17:37 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia, March 08, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, “Telix”, the “Company”) today announces that ZIRCON (Zirconium in Renal Cancer Oncology,...
20170406 Telix Logo.png
Telix Enters Commercial Distribution Agreement for Illuccix® in Australia
February 15, 2022 17:39 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into a commercial distribution agreement with...
20170406 Telix Logo.png
Telix and SHINE partner for Lutetium-177 Supply
February 10, 2022 16:09 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia and INDIANAPOLIS, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a new global clinical supply agreement with...
20170406 Telix Logo.png
Telix Expands Lutetium-177 Network with Eckert & Ziegler Clinical Supply Agreement
February 08, 2022 17:27 ET | Telix Pharmaceuticals Limited
MELBOURNE and LIEGE, Belgium, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces a global clinical supply agreement with Berlin-based...
20170406 Telix Logo.png
Japanese Prostate Cancer Imaging Trial Meets Study Objectives
February 07, 2022 18:08 ET | Telix Pharmaceuticals Limited
MELBOURNE, Australia and KYOTO, Japan, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) in collaboration with Kanazawa University today announces that...